echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca announces phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness

    AstraZeneca announces phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 25, AstraZeneca announced that the main analysis of the Phase 3 clinical trial of the new crown vaccine AZD1222 has obtained high-level positive results.


    AZD1222 is jointly developed by Oxford University and its derivative company Vaccitech.


    Compared with the previous interim analysis, the latest trial results added 49 additional cases and included a total of 190 COVID-19 patients.


    These results have been submitted to the independent Data Security Monitoring Board (DSMB).


    Reference materials:

    [1] AZD1222 US Phase III primary analysis confirms safety and efficacy.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.